Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jul;60(1):91-92.
doi: 10.1111/apt.18048. Epub 2024 May 21.

Editorial: Unravelling real-world impact of second-line therapies in primary biliary cholangitis-Time to change our targets? Authors' reply

C M Fernández-Rodríguez  1   2 , M L Gutierrez  1 , A Olveira  3
Affiliations
Editorial

Editorial: Unravelling real-world impact of second-line therapies in primary biliary cholangitis-Time to change our targets? Authors' reply

C M Fernández-Rodríguez et al. Aliment Pharmacol Ther. 2024 Jul.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Cançado G. Editorial: unraveling real‐world impact of second‐line therapies in primary biliary cholangitis—time to change our targets? Aliment Pharmacol Ther. 2024;60:89–90.
    1. Gómez E, Montero JL, Molina E, Garcia‐Buey L, Casado M, et al. Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: stratifying the impact of add‐on fibrates in real‐world practice. Aliment Pharmacol Ther. 2024;59:1604–1615.
    1. Invernizzi P, Carbone M, Jones D, Levy C, Little N, Wiesel P, et al. Setanaxib, a first‐in‐class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: a randomized, placebo‐controlled, phase 2 trial. Liver Int. 2023;43:1507–1522.
    1. Montali L, Gragnano A, Miglioretti M, Frigerio A, Vecchio L, Gerussi A, et al. Quality of life in patients with primary biliary cholangitis: a cross‐geographical comparison. J Transl Autoimmun. 2021;6(4):100081. https://doi.org/10.1016/j.jtauto.2021.100081
    1. Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares‐da‐Silva MR, Andreone P, et al. Efficacy and safety of Elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390:795–805.

MeSH terms

Substances

LinkOut - more resources